Navigation Links
CuraLase Global, Inc. Now Franchising
Date:3/28/2013

(PRWEB) March 28, 2013

CuraLase Global, Inc. is now expanding franchise opportunities to individuals that may be interested in owning their own clinic. With a proven business plan in place for over 6 years, CuraLase has determined it is the right time to offer this opportunity to others.

In the past 12 months CuraLase has offered limited franchise opportunities in order to put into place a successful franchise business plan. These newest franchises are located in Shenandoah, TX, Mt. Pleasant, SC, and Melbourne, FL. Also, multiple new locations are opening soon.

CuraLase franchise owners are not required to have a medical background. Instead, a CuraLase Franchisee should “be compassionate about helping people that are living with chronic pain, should have some business experience and know how to manage a business. CuraLase Global is looking for individuals committed to developing a new business that is perhaps something they are not familiar with, but it’s a new and rewarding opportunity,” states Daphne Heffler, CuraLase Global Inc. Vice President of Development.    

CuraLase offers non-invasive, drug-free, effective treatment for chronic pain. With an 87% success rate and more than 60,000 treatments administered to patients from over 10 countries, CuraLase is working diligently to establish an international reputation for exceptional patient care. CuraLase therapy is a treatment option that all pain sufferers should consider.

The CuraLase Global Franchising Department is available to answer questions and assist with every aspect of establishing a new franchise.

Related Links:
http://www.curalase.com

# # #
For more information about this topic, contact Paige Kennedy at (843) 294-5273 or pkennedy(at)curalaseglobal(dot)com.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10553639.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
2. Contract Research Organization, WCCT Global, Welcomes Gary Urban as Executive Director, Corporate Compliance and Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Lakes, NJ (PRWEB) , ... December 05, 2016 ... ... recording studio teaming up on new songs with prolific Songwriter-Producer Corey “Chorus” Gibson ... Foxx, Kelly Rowland, Ciara, Brandy…just to name a few.     https://twitter.com/coreychorus , ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... moisture measurements are consistently correct. However, regular performance testing is often neglected ... offers a solution: SmartCal™ . This innovative test substance offers a ...
(Date:12/4/2016)... York, NY (PRWEB) , ... December 03, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – hosted its first Swirl: A Wine Tasting Event in New York ...
(Date:12/4/2016)... ... 04, 2016 , ... "Pro3rd Displace is a set of ... displacement design elements," said Christina Austin - CEO of Pixel Film Studios. ... of design styles that include both left aligned and right aligned options for ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- M ichael Moore ... Chairman   Mission Therapeutics, a drug discovery and ... treat cancer, neurodegenerative and other diseases, announces that Dr ... January 1 st 2017. Dr Colin Goddard ... in July 2015. Michael Moore , Mission,s Founder Chairman, ...
(Date:12/4/2016)... 3, 2016 Johnson & Weaver, LLP announces that ... of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) ... 31, 2016 (the "Class Period"). Zimmer Biomet provides ... orthopaedic reconstructive products, such as knee and hip reconstructive products. ... , , ...
(Date:12/4/2016)... , Dec. 3, 2016  Results from the ... SelG1), an anti-P-selectin antibody, reduced the median annual rate ... to placebo (1.63 vs 2.98, p=0.010) in patients with ... that the data are being featured in the official ... of Hematology (ASH) Annual Meeting and presented during the ...
Breaking Medicine Technology: